Arena Pharmaceuticals ARNA said Thursday Food and Drug Administration advisers recommended approval of the company's diet drug lorcaserin. Arena said it's working with the agency as it finishes its review. A final decision from the FDA could be made June 27. Lorcaserin could be the first new prescription diet drug in over a decade in the U.S. Shares of Arena Pharmaceuticals skyrocketed 96.72% to $7.20 in premarket trading Friday. 3 Hot Stocks for a Sideways Market
Nvidia NVDA , the graphics chipmaker, is scheduled to post first-quarter results Friday. Analysts forecast profit of 10 cents a share in the April-ended period on revenue of $916.2 million. Shares of Nvidia ticked down 7 cents, or 0.56%, in premarket trading Friday to $12.35. LinkedIn Is a Glorified Rolodex
Other companies reporting earnings on Friday include Cache CACH and ReneSola SOL . Cache reported a first-quarter loss of $1.2 million, or 9 cents a share, wider than the year-earlier loss of $772,000, or 6 cents a share. Analysts, on average, expected a loss of 9 cents a share. ReneSola reported first-quarter a loss of $40.2 million, or 23 cents a share, a reversal from year-earlier earnings of $43.3 million, or 24 cents a share. On average, analysts were expecting earnings of 31 cents a share. -- Written by Joseph Woelfel and Alexandra Zendrian >To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: firstname.lastname@example.org.
- Jamie Dimon
- Arena Pharmaceuticals